Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $35
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $34 to $35.
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $34 to $35.